Chloramphenicol Sodium Succinate for Injection 1g

• Application: for Injection
• Usage Mode: I.M./I.V.
• Suitable for: Elderly, Children, Adult
• State: Solid
• Shape: Powder
• Type: Inorganic Chemicals
• Model NO.: 1g
• Pharmaceutical Technology: Chemical Synthesis
• Transport Package: Carton
• Specification: 1g 7ml, 50vials/box
• Trademark: RYAN PHARMA
• Origin: China

Product Description

DESCRIPTION:
Chloramphenicol is an antibiotic that is clinically useful for, and should be reserved for, serious infections caused by organisms susceptible to its antimicrobial effects when less potentially hazardous therapeutic agents are ineffective or contraindicated.  Sensitivity testing is essential to determine its indicated use, but may be performed concurrently with therapy initiated on clinical impression that one of the indicated conditions exists (see INDICATIONS AND USAGE section).
When reconstituted as directed, each vial contains a sterile solution equivalent to 100 mg of chloramphenicol per mL (1 g/10 mL).
Each gram (10 mL of a 10% solution) of chloramphenicol sodium succinate contains approximately 52 mg (2.25 mEq) of sodium.
The chemical name for chloramphenicol sodium succinate is D-threo-(-)-2, 2-Dichloro-N-[β-hydroxy-α-(hydroxymethyl)-p-nitrophenethyl] acetamide α-(sodium succinate).
INDICATIONS AND USAGE:
In accord with the concepts in the Warning Box and this INDICATIONS AND USAGE section, chloramphenicol must be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated.  However, chloramphenicol may be chosen to initiate antibiotic therapy on the clinical impression that one of the conditions below is believed to be present; in vitro sensitivity tests should be performed concurrently so that the drug may be discontinued as soon as possible if less potentially dangerous agents are indicated by such tests.  The decision to continue use of chloramphenicol rather than another antibiotic when both are suggested by in vitro studies to be effective against a specific pathogen should be based upon severity of the infection, susceptibility of the pathogen to the various antimicrobial drugs, efficacy of the various drugs in the infection, and the important additional concepts contained in the Warning Box above.
 
    It is not recommended for the routine treatment of the typhoid carrier state.
•  Serious infections caused by susceptible strains in accordance with the concepts expressed above:
   a) Salmonella species
   b) H. influenzae, specially meningeal infections
   c) Rickettsia
   d) Lymphogranuloma-psittacosis group
   e) Various gram-negative bacteria causing bacteremia, meningitis or other serious gram-negative infections.
   f)  Other susceptible organisms which have been demonstrated to be resistant to all other appropriate antimicrobial agents.
•   Cystic fibrosis regimens
*In treatment of typhoid fever some authorities recommend that chloramphenicol be administered at therapeutic levels for 8 to 10 days after the patient has become afebrile to lessen the possibility of relapse.
CONTRAINDICATIONS:
 Chloramphenicol is contraindicated in individuals with a history of previous hypersensitivity and/or toxic reaction to it.  It must not be used in the treatment of trivial infections or where it is not indicated, as in colds, influenza, infections of the throat; or as a prophylactic agent to prevent bacterial infections.
DOSAGE AND ADMINISTRATION:
Chloramphenicol, like other potent drugs, should be prescribed at recommended doses known to have therapeutic activity.  Administration of 50 mg/kg/day in divided doses will produce blood levels of the magnitude to which the majority of susceptible microorganisms will respond.
As soon as feasible an oral dosage form of another appropriate antibiotic should be substituted for intravenous chloramphenicol sodium succinate.
The following method of administration is recommended:
Intravenously as a 10% (100 mg/mL) solution to be injected over at least a one-minute interval.  This is prepared by the addition of 10 mL of an aqueous diluent such as water for injection or 5% dextrose injection.
Adults
Adults should receive 50 mg/kg/day in divided doses at 6-hour intervals.  In exceptional cases patients with infections due to moderately resistant organisms may require increased dosage up to 100 mg/kg/day to achieve blood levels inhibiting the pathogen, but these high doses should be decreased as soon as possible.  Adults with impairment of hepatic or renal function or both may have reduced ability to metabolize and excrete the drug.  In instances of impaired metabolic processes, dosages should be adjusted accordingly. Precise control of concentration of the drug in the blood should be carefully followed in patients with impaired metabolic processes by the available microtechniques.